---
title: "Ensysce Biosciences, Inc. (ENSC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ENSC.US.md"
symbol: "ENSC.US"
name: "Ensysce Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T15:29:44.828Z"
locales:
  - [en](https://longbridge.com/en/quote/ENSC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ENSC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ENSC.US.md)
---

# Ensysce Biosciences, Inc. (ENSC.US)

## Company Overview

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ensysce.com](https://www.ensysce.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: D (0.69)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 324 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -24.36% |  |
| Net Profit YoY | -72.92% |  |
| P/B Ratio | -8.08 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2749017.77 |  |
| Revenue | 4707877.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -870.19% | E |
| Profit Margin | -250.36% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | -24.36% | E |
| Net Profit YoY | -72.92% | E |
| Total Assets YoY | -53.00% | E |
| Net Assets YoY | -124.59% | E |
| Cash Flow Margin | 81.45% | C |
| OCF YoY | -24.36% | E |
| Turnover | 1.39 | A |
| Gearing Ratio | 130.86% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ensysce Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-24.36%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.92%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-8.08",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2749017.77",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4707877.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-870.19%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-250.36%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-24.36%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.92%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-53.00%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-124.59%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "81.45%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-24.36%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "1.39",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "130.86%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.23 | 94/386 | - | - | - |
| PB | -8.08 | 519/386 | 2.38 | 1.77 | 1.20 |
| PS (TTM) | 0.58 | 12/386 | 0.90 | 0.81 | 0.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.29 |
| Highest Target | 16.45 |
| Lowest Target | 16.45 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ENSC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ENSC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ENSC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ENSC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**